Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

Novo Nordisk ... at Clayton in North Carolina, will focus on producing active pharmaceutical ingredients (APIs) for isemaglutide and other diabetes drugs, while the Danish plant in Måløv will ...

Novo Nordisk has been manufacturing some active pharmaceutical ingredients, and finished products, in the US, and is investing further, with a $4.1bn factory in North Carolina announced last year.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

Eli Lilly has invested $5.3 billion to expand manufacturing capacity, while Novo Nordisk is building a $4.1 billion fill-finish plant in Clayton, North Carolina. However, these expansions take ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human therapeutics, will collaborate with Novo Nordisk A/S to co ... for research ...

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.